(Q37433033)

20 August 2017

1 reference

title

Lipid lowering for primary prevention (English)

1 reference

20 August 2017

1

Salim Yusuf

1 reference

20 August 2017

Eva Lonn

2

1 reference

20 August 2017

Jackie Bosch

series ordinal

3

1 reference

20 August 2017

language of work or name

English

0 references

publication date

1 April 2009

1 reference

20 August 2017

1 reference

20 August 2017

volume

373

1 reference

20 August 2017

issue

9670

1 reference

20 August 2017

page(s)

1152-1155

1 reference

Rosuvastatin in older patients with systolic heart failure

20 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960357-3

7 January 2021

Effect of rosuvastatin in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960357-3

7 January 2021

Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960357-3

7 January 2021

Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960357-3

7 January 2021

Primary prevention of cardiovascular mortality and events with statin treatments: a network meta-analysis involving more than 65,000 patients.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960357-3

7 January 2021

Intensive lipid lowering with simvastatin and ezetimibe in aortic stenosis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960357-3

7 January 2021

Pravastatin and the development of diabetes mellitus: evidence for a protective treatment effect in the West of Scotland Coronary Prevention Study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960357-3

7 January 2021

Narrative review: Assessment of C-reactive protein in risk prediction for cardiovascular disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960357-3

7 January 2021

A strategy to reduce cardiovascular disease by more than 80%

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960357-3

7 January 2021

The need to test the theories behind the Polypill: rationale behind the Indian Polycap Study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960357-3

7 January 2021

Amino-terminal pro-B-type natriuretic peptide and B-type natriuretic peptide: biomarkers for mortality in a large community-based cohort free of heart failure

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960357-3

7 January 2021

10.1016/S0140-6736(09)60357-3

Identifiers

DOI

1 reference

20 August 2017

1 reference